Answers are grounded in this paper and cite their sources.
Pimavanserin, a novel agent approved for the treatment of Parkinson's disease psychosis, has potent actions as an antagonist/inverse agonist at serotonin 5HT2A receptors and less potent antagonist/inverse agonist actions at 5HT2C receptors.
No takes yet. Share an insight, caveat, or question.
Stephen M. Stahl (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: